BlackRock
SABS icon

BlackRock’s SAB Biotherapeutics SABS Stock Holding History

BlackRock’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.3M Buy
3,572,073
+506,057
+17% +$1.84M ﹤0.01% 3606
2026
Q2 		$12M Buy
3,066,016
+2,764,690
+918% +$10.3M ﹤0.01% 3582
2026
Q1 		$1.15M Buy
301,326
+284,087
+1,648% +$1.13M ﹤0.01% 4287
2025
Q4 		$64.5K Buy
17,239
+10,900
+172% +$35.9K ﹤0.01% 4996
2025
Q3 		$12.7K Sell
6,339
-667
-10% -$1.51K ﹤0.01% 5198
2025
Q2 		$12.3K Sell
7,006
-15,295
-69% -$25.3K ﹤0.01% 5199
2025
Q1 		$30.3K Sell
22,301
-303
-1% -$695 ﹤0.01% 5020
2024
Q4 		$85.8K Buy
22,604
+439
+2% +$1.44K ﹤0.01% 4821
2024
Q3 		$59.8K Buy
22,165
+8,413
+61% +$23.3K ﹤0.01% 4772
2024
Q2 		$42.6K Buy
13,752
+7,413
+117% +$27.2K ﹤0.01% 4897
2024
Q1 		$28.8K Buy
6,339
+1,075
+20% +$5.92K ﹤0.01% 4980
2023
Q4 		$36.2K Hold
5,264
– – ﹤0.01% 5015
2023
Q3 		$33.2K Hold
5,264
– – ﹤0.01% 5075
2023
Q2 		$43.7K Sell
5,264
-5,737
-52% -$47K ﹤0.01% 5085
2023
Q1 		$48.4K Buy
11,001
+186
+2% +$1.18K ﹤0.01% 5125
2022
Q4 		$63.8K Sell
10,815
-1,757
-14% -$16.1K ﹤0.01% 5163
2022
Q3 		$88K Sell
12,572
-173
-1% -$1.72K ﹤0.01% 5216
2022
Q2 		$185K Buy
12,745
+5,493
+76% +$115K ﹤0.01% 5057
2022
Q1 		$273K Buy
7,252
+91
+1% +$4.2K ﹤0.01% 5036
2021
Q4 		$559K Buy
+7,161
New +$672K ﹤0.01% 4839

Other funds holding SABS

Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Propel Bio Management
Propel Bio Management Los Angeles, California $189M AUM 71.31% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

BlackRock's SABS Position: Q3 2026 in Review

BlackRock increased its SAB Biotherapeutics (SABS) stake by 17% in Q3 2026, buying an estimated $1.84M and bringing the position to 3,572,073 shares worth $11.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3606.

BlackRock first reported a position in SABS in Q4 2021 and has held it in 20 quarters since. The position peaked at $12M in Q2 2026. 61 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • BlackRock held 3,572,073 shares of SAB Biotherapeutics worth $11.3M as of Q3 2026.
  • BlackRock bought 506,057 SAB Biotherapeutics shares in Q3 2026, an estimated $1.84M.
  • SAB Biotherapeutics made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #3606 holding.
  • BlackRock first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 20 quarters since.
  • BlackRock's SAB Biotherapeutics position peaked at $12M in Q2 2026.
  • 61 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.